{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:55:59Z","timestamp":1790920559521,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.drugalcdep.2009.08.003","type":"journal-article","created":{"date-parts":[[2009,9,20]],"date-time":"2009-09-20T08:21:28Z","timestamp":1253434888000},"page":"S42-S55","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S1","title":["Case histories in pharmaceutical risk management"],"prefix":"10.1016","volume":"105","author":[{"given":"Cynthia G.","family":"McCormick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. David","family":"Haddox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajan","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Wissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence P.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolley E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2009.08.003_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1369.065","article-title":"Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics","volume":"1074","author":"Abanades","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.annemergmed.2005.10.012","article-title":"Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003","volume":"47","author":"Anderson","year":"2006","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.annemergmed.2008.07.015","article-title":"The underrecognized toll of prescription opioid abuse on young children","volume":"53","author":"Bailey","year":"2009","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130050092","article-title":"Evaluation of the discriminative stimulus and reinforcing effects of gammahyroxybutyrate (GHB)","volume":"127","author":"Beardsley","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib6","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/15563650701754763","article-title":"2006 Annual Report of the American Association of Poison Control Centers\u2019 National Poison Data System (NPDS)","volume":"45","author":"Bronstein","year":"2007","journal-title":"Clin. Toxicol."},{"issue":"November","key":"10.1016\/j.drugalcdep.2009.08.003_bib7","first-page":"A1","article-title":"Narcotic \u2018lollipop\u2019 is big seller despite FDA curbs","author":"Carreyou","year":"2006","journal-title":"Wall Street J."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib8","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","article-title":"Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB","volume":"31","author":"Carter","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0376-8716(99)00041-1","article-title":"A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States","volume":"57","author":"Cicero","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1526-4637.2006.00259.x","article-title":"The development of a comprehensive risk-management program for prescription opioid analgesics: Researched, Abuse, Diversion and Addiction-Related Surveillance (RADARS\u00ae)","volume":"8","author":"Cicero","year":"2007","journal-title":"Pain Med."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib11","doi-asserted-by":"crossref","first-page":"302","DOI":"10.5055\/jom.2007.0018","article-title":"Use and misuse of buprenorphine in the management of opioid addiction","volume":"3","author":"Cicero","year":"2007","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib12","series-title":"Presented at the Buprenorphine Summit","article-title":"Verispan Total Patient Tracker","author":"Clark","year":"2008"},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib13","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.drugalcdep.2009.08.011","article-title":"Monitoring risk: post marketing surveillance and signal detection","volume":"105","author":"Dart","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib14","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.drugalcdep.2009.05.019","article-title":"Signal detection in post-marketing surveillance for controlled substances","volume":"105","author":"Dasgupta","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib15","unstructured":"Denver Health and Hospital Authority, 2008a. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS\u00ae) System. Available at: http:\/\/www.radars.org (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib16","unstructured":"Denver Health and Hospital Authority, 2008b. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS\u00ae) System 2nd Quarter 2008 Shire Development, Inc. Report of Amphetamine Data. November 2008."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib17","unstructured":"Denver Health and Hospital Authority, 2008c. Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS\u00ae) System 2nd Quarter 2008 Shire Development, Inc. Report of Methylphenidate Data. October 2008."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib18","unstructured":"Drug Abuse Warning Network, 2008. Available at: http:\/\/dawninfo.samhsa.gov\/ (accessed December 17, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib19","unstructured":"Drug Addiction Treatment Act-2000\u2014Public Law 106\u2013310 Title XXXV Waiver Authority for Physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. Section 3501\u20133502. Available at: http:\/\/buprenorphine.samhsa.gov\/fulllaw.html (accessed on August 17, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib20","unstructured":"Drug Enforcement Administration, 2002. Schedule of Controlled Substances; Rrescheduling of Buprenorphine from Schedule V to Schedule III. Federal Register 67(194 (October 7)) 62354."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib21","unstructured":"Drug Enforcement Administration, 2009. Title 21\u2014Food and Drugs Chapter 13. Drug Abuse and Prevention and Control. Available at: http:\/\/www.usdoj.gov\/dea\/pubs\/csa.html (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib22","unstructured":"Food and Drug Administration, 1998. FDA approves Actiq for marketing: drug offers cancer patients relief from breakthrough cancer pain. Available at: http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/ANS00921.html (accessed on May 28, 2009)"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib23","unstructured":"Food and Drug Administration, 2002. Suboxone administrative documents and correspondence, 2002. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/20-733_Subutex_AdminCorres_P1.pdf (accessed on March 6, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib24","unstructured":"Food and Drug Administration, 2002a. Approval History \u2013 Suboxone \u2013 Review \u2013 Administrative Documents & Correspondence Part 1. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/20-733_Subutex_AdminCorres_P1.pdf (accessed on November 28, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib25","unstructured":"Food and Drug Administration, 2002b. Approval Letter \u2013 Suboxone. Available at: http:\/\/www.fda.gov\/cder\/foi\/nda\/2002\/20-733_Subutex_Approv.pdf (accessed on November 28, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib26","unstructured":"Food and Drug Administration, 2002c. Anesthetic and Life Support Drugs Advisory Committee meeting dated January 31, 2002. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/02\/transcripts\/3820t2.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib27","unstructured":"Food and Drug Administration, 2004. FDA announces enhancement to Isotretinoin Risk Management Program. Available at: http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/2004\/ANS01328.html (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib28","unstructured":"Food and Drug Administration, 2005a. Guidance for industry: premarketing risk assessment. Available at: http:\/\/www.fda.gov\/cder\/guidance\/6357fnl.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib29","unstructured":"Food and Drug Administration, 2005b. Development and Use of Risk Minimization Action Plans. Available at: http:\/\/www.fda.gov\/cder\/guidance\/6358fnl.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib30","unstructured":"Food and Drug Administration, 2005c. Good pharmacovigilance practices and pharmacoepidemiologic assessment. Available at: http:\/\/www.fda.gov\/cder\/guidance\/6359OCC.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib31","unstructured":"Food and Drug Administration, 2007. Food and Drug Administration Amendments Act of 2007. Congressional Record, 2007. Pub. L. No. 110-85, \u00a7 505-1 (2007)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib32","unstructured":"U.S. General Accounting Office, 2003. Prescription drugs: OxyContin abuse and diversion and efforts to address the problem. Available at: http:\/\/www.gao.gov\/new.items\/d04110.pdf (accessed on March 25, 2009)."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib33","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.drugalcdep.2009.08.004","article-title":"Commentary: risk management and post-marketing surveillance of CNS drugs","volume":"105","author":"Henningfield","year":"2009","journal-title":"Drug Alcohol Depend."},{"issue":"November","key":"10.1016\/j.drugalcdep.2009.08.003_bib34","first-page":"125","article-title":"The diversion of prescription opioid analgesics","author":"Inciardi","year":"2007","journal-title":"Law Enforcement Executive Forum"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib35","unstructured":"Inflexxion, 2009a. MyStudentBody. Available at: http:\/\/www.inflexxion.com\/offerings.aspx?id=468 (accessed May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib36","unstructured":"Inflexxion, 2009b. InsideADHD.org. Available at: http:\/\/www.insideadhd.org\/ (accessed May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib37","unstructured":"Jazz Pharmaceuticals Inc., 2008. Xyrem. Available at: http:\/\/www.xyrem.com (accessed on December 1, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib38","unstructured":"JBS International, 2006. Diversion and abuse of buprenorphine: a brief assessment of emerging indicators, 2006. Available at: http:\/\/buprenorphine.samhsa.gov\/Buprenorphine_FinalReport_12.6.06.pdf (accessed on November 28, 2008)."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib39","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.drugalcdep.2009.08.006","article-title":"Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report","volume":"105","author":"Johanson","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib40","unstructured":"Johnston, L.D., O\u2019Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2007. Monitoring the Future national results on adolescent drug use: overview of key findings, 2007. Available at: http:\/\/monitoringthefuture.org\/pubs\/monographs\/overview2007.pdf (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib41","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nn1583","article-title":"Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction","volume":"8","author":"Kreek","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib42","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.drugalcdep.2009.02.007","article-title":"Risk management of drug products and the FDA: Evolution and context","volume":"105","author":"Leiderman","year":"2009","journal-title":"Drug Alcohal Depend"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib43","unstructured":"National Drug Intelligence Center U.S. Department of Justice, 2007. National Drug Threat Assessment 2008. Available at: http:\/\/www.usdoj.gov\/ndic\/topics\/ndtas.htm#y2008 (accessed on July 17, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib44","unstructured":"National Forensic Laboratory Information System, 2009. U.S. Drug Enforcement Administration Office of Diversion Control. 2000\u20132007 annual reports. Available at: http:\/\/www.deadiversion.usdoj.gov\/nflis\/index.html (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib45","unstructured":"Neuman, A., 2004. GHB's path to legitimacy: an administrative and legislative history of Xyrem. Available at: http:\/\/leda.law.harvard.edu\/leda\/data\/629\/Neuman.html (accessed on February 23, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib46","unstructured":"PRN Newswire, 2007. Barr Pharmaceuticals. Barr and Shire sign three agreements: a product acquisition agreement for ADDERALL(\u00ae); a product development agreement; and a settlement and license agreement for ADDERALL XR(\u00ae). [Internet] New Jersey: 2006 August 14. Available from: http:\/\/www.prnewswire.com\/cgi-bin\/stories.pl?ACCT=104&STORY=\/www\/story\/08-14-2006\/0004416042 (accessed on May 31, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib47","unstructured":"Purdue Pharma, 2002. Press release: Purdue Pharma implements national surveillance system to track diversion and abuse of controlled pain medications. Available at: http:\/\/www.purduepharma.com\/pressroom\/news\/oxycontinnews\/20020627.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib48","unstructured":"Purdue Pharma, 2003. Press release: Purdue Pharma sponsors ten communities that care locations \u2013 Grants total $250,000. Available at: http:\/\/www.purduepharma.com\/pressroom\/news\/oxycontinnews\/20031218-01.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib49","unstructured":"Purdue Pharma, 2004. Press release: Purdue Pharma comments on GAO report on OxyContin abuse and diversion. Available at: http:\/\/www.purduepharma.com\/pressroom\/news\/oxycontinnews\/20040122-01.htm (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib50","unstructured":"Purdue Pharma, 2007a. OxyContin full prescribing information. Available at: http:\/\/www.purduepharma.com\/PI\/Prescription\/Oxycontin.pdf (accessed on December 17, 2008)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib51","unstructured":"Purdue Pharma, 2007b. MS Contin full prescribing information. Available at: http:\/\/www.purduepharma.com\/PI\/Prescription\/MS_Contin.pdf (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib52","unstructured":"Purdue Pharma, 2009. Rx pattern analysis tracking robberies & other losses. Available at: http:\/\/www.rxpatrol.com (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib53","unstructured":"Reinberg, S., 2007. Congress moves closer to drug-safety bill. Washington Post. http:\/\/www.washingtonpost.com\/wp-dyn\/content\/article\/2007\/07\/12\/AR2007071201833.html (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s002130051030","article-title":"Zaleplon and triazolam in humans: acute behavioral effects and abuse potential","volume":"145","author":"Rush","year":"1999","journal-title":"Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2009.08.003_bib55","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.drugalcdep.2009.08.005","article-title":"Introduction to College on Problems of Drug Dependence special Conference on risk management and post-marketing surveillance of CNS drugs","volume":"105","author":"Schuster","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.healthpol.2007.08.006","article-title":"Ten years after the Rx-to-OTC switch of nicotine replacement therapy: What have we learned about the benefits and risks of non-prescription availability?","volume":"86","author":"Shiffman","year":"2008","journal-title":"Health Policy"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib57","unstructured":"Shire Pharmaceuticals, 2006a. Shire and Barr settle all pending litigation concerning ADDERALL XR\u00ae and enter into development and license agreement. Available at: http:\/\/www.shire.com\/shire\/NewsAndMedia\/PressReleases\/showShirePress.jsp?ref=581&tn=&m1=&m2= (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib58","unstructured":"Shire Pharmaceuticals, 2006b. Ensuring appropriate use of stimulants: a parents\u2019 guide to being AWARE. Available at: http:\/\/www.daytrana.com\/downloads\/AWAREBrochure.pdf (accessed on February 20, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib59","unstructured":"Shire Pharmaceuticals, 2008a. Daytrana (methylphenidate transdermal patch) prescribing information. Available at: http:\/\/www.daytrana.com\/downloads\/DaytranaPrescribingInfo.pdf (accessed on February 23, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib60","unstructured":"Shire Pharmaceuticals, 2008b. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Available at: http:\/\/www.vyvanse.com\/pdf\/prescribing_information.pdf (accessed on February 23, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib61","first-page":"19","article-title":"Risk management programs: a supplement to the Controlled Substances Act","volume":"4","author":"Schnoll","year":"2006","journal-title":"Food Drug Law Inst."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib62","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0376-8716(03)00096-6","article-title":"Keeping the lid on: a century of drug regulation and control","volume":"70","author":"Spillane","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib63","unstructured":"Substance Abuse and Mental Health Services Administration, 2001. Opioid drugs in maintenance and detoxification treatment of opiate addiction, Final Rule. 21 CFR Part 291, 42 CFR Part 8. Federal Register, 66, 4076-4102, 2001. Available at: http:\/\/www.dpt.samhsa.gov\/pdf\/regs.pdf (accessed on August 17, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib64","series-title":"Results from the 2002 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2003"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib65","series-title":"Results from the 2003 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2004"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib66","series-title":"Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-Related Emergency Department Visits","author":"Substance Abuse and Mental Health Services Administration","year":"2004"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib67","series-title":"Results from the 2004 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2005"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib68","series-title":"Results from the 2005 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2006"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib69","series-title":"Drug Abuse Warning Network, 2004: National Estimates of Drug-related Emergency Department Visits","author":"Substance Abuse and Mental Health Services Administration","year":"2006"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib70","unstructured":"Substance Abuse and Mental Health Services Administration, 2006c. DAWN Live! Available at: http:\/\/dawninfo.samhsa.gov\/build\/whyhospitalsjoin\/ed_dawnlive.asp (accessed on May 28, 2009)."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib71","series-title":"Results from the 2006 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2007"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib72","unstructured":"Substance Abuse and Mental Health Services Administration, 2007b. DAWN Live! October 2, 2007; as presented by Dr. Westley Clark, MD, JD, MPH at buprenorphine summit on February 21, 2008."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib73","series-title":"Results from the 2007 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2008"},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/157488606775252647","article-title":"The clinical development of \u03b3-hydroxybutyrate (GHB)","volume":"1","author":"Wedin","year":"2006","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2009.08.003_bib75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0376-8716(98)00153-7","article-title":"Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys","volume":"54","author":"Woolverton","year":"1999","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609003214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871609003214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T18:56:08Z","timestamp":1558551368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871609003214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":75,"alternative-id":["S0376871609003214"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.08.003","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}